Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population

Journal of Dermatological Treatment

Volumn 24, Issue 1, 2013, Pages 25-33

  Chastek, Benjamin ^a   Fox, Kathleen M ^b   Watson, Crystal ^c   Kricorian, Gregory ^c   Gandra, Shravanthi R ^c  

^a OPTUM   (United States)

^b Strategic Healthcare Solutions LLC   (United States)

^c AMGEN INC   (United States)

Author keywords

Adalimumab; Etanercept; Psoriasis; Treatment patterns

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; EFALIZUMAB; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; USTEKINUMAB;

ADULT; AGE DISTRIBUTION; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE PLANNING; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; TREATMENT DURATION; UNITED STATES;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG UTILIZATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; STATE HEALTH PLANS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84872298180     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.661038     Document Type: Article

References (12)

1. Lebwohl M. Psoriasis. Lancet. 2003;361:1197-1204.
2. American Academy of Dermatology. What is psoriasis? 2011. 8-6-2007.
3. Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol. 2008;59: 772-780.
4. Bonifati C, Ameglio F. Cytokines in psoriasis. Int J Dermatol. 1999;38:241-251.
5. Mussi A, Bonifati C, Carducci M, D'Agosto G, Pimpinelli F, D'Urso D, et al. Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis. J Biol Regul Homeost Agents. 1997;11: 115-118.
6. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNFalpha) biological activity in psoriatic skin lesions. Clin Exp Immunol. 1994;96:146-151.
7. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68:702-709.
8. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272.
9. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227-1236.
10. Thayer S, Watson C, Song R, Globe DR, Harrison DJ. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. J Med Econ. 2010;13: 228-235.
11. Public Law 104-191 1C. Health Insurance Portability and Accountability Act of 1996. 2009. 6-17-2011.
12. Richards HL, Ray DW, Kirby B, Mason D, Plant D, Main CJ, et al. Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol. 2005;153:1114-1120.